MaxCyte to acquire Akron BioProducts for $152M

Q: How much is MXCT paying for Akron Bio?

MaxCyte stated total consideration of $151.8 million: $105.0 million cash at closing, 20,639,733 shares valued at approximately $26.8 million based on the November 9, 2026 closing price, and $20.0 million in guaranteed deferred cash payments. The deferred amount is payable in $10.0 million installments on the first business day of January 2028 and January 2029.

Q: What were MXCT’s third-quarter 2026 revenue and net loss?

MXCT reported third-quarter 2026 revenue of $10.152 million, up 49% from $6.829 million in 2025. Core revenue was $8.157 million, up 27% from $6.406 million, and net loss was $4.762 million compared with $12.416 million.

Third-quarter revenue rose 49% year over year, and MaxCyte raised its full-year 2026 total revenue guidance.

Available on EDGAR 11/10/2026 - 08:21 AM EST Accepted by SEC EDGAR 11/10/2026 - 08:21 AM EST

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

MaxCyte agreed to acquire Akron BioProducts LLC for stated total consideration of $151.8 million. Terms provide for $105.0 million cash at closing, 20,639,733 common shares, and $20.0 million in guaranteed deferred cash payments, payable in $10.0 million installments on the first business day of January 2028 and January 2029. Closing is expected before the end of 2026, subject to customary conditions including expiration or termination of the Hart-Scott-Rodino waiting period and Nasdaq listing approval for the shares; no financing or stockholder-approval condition applies.

MaxCyte secured a MidCap Financial credit facility of up to $75.0 million, comprising a $55.0 million term loan and a $20.0 million revolver; it expects to draw $20.0 million and $2.0 million, respectively, at closing. The company says the acquisition is expected to nearly double its revenue base.

Third-quarter revenue was $10.152 million, up 49% year over year, and core revenue was $8.157 million, up 27%. Net loss was $4.762 million versus $12.416 million a year earlier. Total cash, cash equivalents and investments were $132.7 million as of September 30, 2026. MaxCyte raised 2026 total revenue guidance.

3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

Major point. Forward-looking: it has not happened yet and may not happen.The proposed Akron acquisition is projected to nearly double MaxCyte’s revenue base.
Moderate pointThird-quarter revenue increased 49% year over year to $10.152 million.
Moderate pointNet loss narrowed to $4.762 million from $12.416 million in third-quarter 2025.

Negative

Major point. Forward-looking: it has not happened yet and may not happen.Planned closing issuance of 20,639,733 shares carries the dilution risk identified by MaxCyte.

Filing Explained

At closing, MaxCyte is to issue 20,639,733 shares to the sellers without registration under an exemption; they will be locked up for six months and covered by resale-registration rights, and the filing identifies the issuance as dilutive to existing holders.

8-K Event Classification

5 items: 1.01, 2.02, 3.02, 7.01, 9.01

5 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Total revenue: $10.152 million Core revenue: $8.157 million Net loss: $4.762 million +5 more

8 metrics

Total revenue $10.152 million Third quarter 2026; up 49% from $6.829 million in third quarter 2025

Core revenue $8.157 million Third quarter 2026; up 27% from $6.406 million in third quarter 2025

Net loss $4.762 million Third quarter 2026, compared with $12.416 million in third quarter 2025

Cash, cash equivalents and investments $132.7 million As of September 30, 2026

Acquisition consideration $151.8 million Total consideration for Akron Bio

Stock consideration 20,639,733 shares Shares to be issued to the sellers at closing

Cash payable at closing $105.0 million Akron acquisition consideration

Credit facility Up to $75.0 million New MidCap Financial facility

Key Terms

Strategic Platform License (SPL) Program-related revenue, EBITDA, drug master files (DMFs), GMP-grade, +1 more

5 terms

EBITDA financial

"EBITDA, a non-GAAP measure, was a loss of $5.1 million"

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.

drug master files (DMFs) regulatory

"drug master files (DMFs) referenced in INDs and BLAs"

Drug master files (DMFs) are confidential submissions to health regulators that contain detailed technical information about how a drug ingredient or component is made, tested and controlled, allowing a manufacturer to share safety and quality data without exposing proprietary trade secrets. For investors, DMFs are a signal that a company’s supply chain and manufacturing practices are documented and inspectable, which can help speed approvals, reduce regulatory risk and protect product continuity—think of them as locked blueprints that reassure regulators and partners that a product can be produced reliably.

GMP-grade technical

"GMP-grade reagents and ancillary materials used throughout the cell therapy manufacturing workflow"

GMP-grade means a drug substance, ingredient or product was manufactured under Good Manufacturing Practice standards — a set of rules and documented controls that ensure consistent cleanliness, quality and traceability. For investors, GMP-grade items matter because they lower regulatory and safety risk, make products eligible for approval and sale in regulated markets, and reduce the chance of costly recalls or supply disruptions; think of it like food prepared in a certified commercial kitchen rather than a home stove.

Hart-Scott-Rodino Antitrust Improvements Act regulatory

"waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"

A U.S. law that requires companies planning large mergers or acquisitions to notify federal antitrust authorities and wait for review before completing the deal. Think of it like applying for a building permit: regulators check whether the combined business would unfairly hurt competition and can clear the deal, impose changes, or seek to stop it, so the process affects transaction timing, cost, and whether expected benefits reach investors.

Earnings Snapshot

Revenue: $10.152 million · Guidance included

Three months ended September 30, 2026

Revenue $10.152 million +49% year over year

Core revenue $8.157 million +27% year over year

Net loss $4.762 million $12.416 million loss in third quarter 2025

Gross margin 83% 77% in third quarter 2025

Guidance

Raised full-year 2026 total revenue guidance

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is MXCT paying for Akron Bio?

MaxCyte stated total consideration of $151.8 million: $105.0 million cash at closing, 20,639,733 shares valued at approximately $26.8 million based on the November 9, 2026 closing price, and $20.0 million in guaranteed deferred cash payments. The deferred amount is payable in $10.0 million installments on the first business day of January 2028 and January 2029.

What were MXCT’s third-quarter 2026 revenue and net loss?

MXCT reported third-quarter 2026 revenue of $10.152 million, up 49% from $6.829 million in 2025. Core revenue was $8.157 million, up 27% from $6.406 million, and net loss was $4.762 million compared with $12.416 million.

What restrictions apply to the MXCT acquisition shares?

The 20,639,733 shares issued as stock consideration will be subject to a six-month lock-up following closing. At closing, MaxCyte and the sellers will enter into a registration rights agreement providing for registration of the resale of those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2026

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40674		52-2210438
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

(301) 944-1700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 par value

MXCT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

On November 9, 2026, MaxCyte, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Ohio TopCo LP and Arcline Capital Partners A LP (together, the “Sellers”), affiliates of Arcline Investment Management, and the other parties thereto, pursuant to which the Company will acquire, indirectly, all of the outstanding equity interests of Akron BioProducts LLC (“Akron”) (the “Acquisition”).

The consideration for the Acquisition consists of (i) $105.0 million in cash payable at the closing of the Acquisition (the “Closing”), subject to customary adjustments, (ii) 20,639,733 shares (the “Stock Consideration”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), and (iii) $20.0 million in guaranteed, deferred cash payments, consisting of $10.0 million each, payable on the first business day of 2028 and the first business day of 2029.

The Purchase Agreement contains customary representations, warranties and covenants. The representations and warranties of the parties do not survive the Closing. Concurrently with the execution of the Purchase Agreement, the Company obtained a conditional binder for a buyer-side representations and warranties insurance policy, which will provide the Company’s sole recourse with respect to losses arising from breaches of the representations and warranties of the Sellers in the Purchase Agreement, except for claims against a Seller for fraud committed by such Seller. The Closing is subject to customary closing conditions, including the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the approval of the Stock Consideration for listing on The Nasdaq Stock Market LLC, and is not subject to a financing condition or the approval of the Company’s stockholders. The Purchase Agreement may be terminated under customary circumstances, including if the Closing has not occurred within 120 days after the date of the Purchase Agreement. The Closing is expected to occur before the end of 2026. The Stock Consideration will be subject to a six-month lock-up following the Closing, and at the Closing the Company and the Sellers will enter into a registration rights agreement providing for the registration of the resale of the Stock Consideration.

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K, incorporated herein by reference. The Purchase Agreement is not intended to provide any factual information about the Company, the Sellers or Akron. The representations and warranties contained therein were made solely for the benefit of the parties thereto, are subject to limitations agreed upon by the parties, including confidential disclosure schedules, and should not be relied upon as characterizations of the actual state of facts.

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2026, the Company issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

Item 3.02. Unregistered Sales of Equity Securities.

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Stock Consideration is incorporated herein by reference. The 20,639,733 shares of Common Stock comprising the Stock Consideration will be issued to the Sellers at the Closing in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, based in part on the Sellers’ representations that each is an “accredited investor” (as defined in Rule 501(a) of Regulation D) acquiring the shares for investment.

Item 7.01. Regulation FD Disclosure.

On November 10, 2026, the Company issued a press release announcing the Acquisition, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K. A copy of the investor presentation regarding the Acquisition is furnished as Exhibit 99.3 to this Current Report on Form 8-K. A copy of the Company’s corporate presentation is furnished as Exhibit 99.4 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing and completion of the Acquisition and the related financing, the anticipated benefits of the Acquisition, and the expected registration and resale of the Stock Consideration. These statements are subject to risks and uncertainties, including that the conditions to the Closing, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, may not be satisfied, on a timely basis or at all; that the Acquisition or the financing may not be completed on the expected terms or timeline or at all; the occurrence of any event, change or other circumstance that could give rise to the termination of the Purchase Agreement; the Company’s ability to successfully integrate Akron’s business, operations and personnel and to realize the anticipated benefits of the Acquisition; the dilution to the Company’s existing stockholders resulting from the issuance of the Stock Consideration; the potential impact on the market price of the Common Stock of resales of the Stock Consideration following the expiration of the lock-up period, including pursuant to the registration rights agreement; the Company’s indebtedness under the anticipated senior secured credit facility and its obligation to make the deferred cash payments, which may become immediately due and payable upon the occurrence of certain events, including a change of control of the Company, a payment default, insolvency or the acceleration of certain other indebtedness; and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description

2.1		Securities Purchase Agreement, dated as of November 9, 2026, by and among Ohio TopCo LP, Arcline Capital Partners A LP, Ohio Intermediate LLC, Arcline Ohio Blocker LLC and MaxCyte, Inc. *†
99.1		Press Release, dated November 10, 2026
99.2		Press Release, dated November 10, 2026
99.3		Investor Presentation, dated November 10, 2026
99.4		Corporate Presentation, dated November 2026
104		Cover Page Interactive Data (embedded within the Inline XBRL document)

* Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.

† Certain identified information has been excluded from this exhibit pursuant to Item 601(b)(2)(ii) of Regulation S-K because it is both (i) not material and (ii) the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of this exhibit to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MaxCyte, Inc.

Dated: November 10, 2026	By:	/s/ Parmeet Ahuja
		Parmeet Ahuja
		Chief Financial Officer

Exhibit 99.1

MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

MaxCyte will host its third quarter 2026 earnings call today, November 10^th, at 8:30 a.m. Eastern Time

Third Quarter and Recent Business Highlights:

Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related revenue

Raises Full Year 2026 Total Revenue Guidance to at least $34.5 million, reflecting a projected return to full-year revenue growth

In July, MaxCyte announced a strategic, multi-platform technology license partnership with Genentech

MaxCyte today announced the proposed acquisition of Akron Bio, a leading supplier of GMP-grade reagents and ancillary materials, expanding its offering across cell therapy manufacturing and nearly doubling revenue

"Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value,” said Maher Masoud, President and CEO of MaxCyte. “MaxCyte’s third quarter results reflect the progress that we have made throughout 2026, with approximately 15% year-over-year core revenue growth expected in the second half of this year, exceeding the growth expectations we established at the beginning of 2026. Looking ahead, our SPL partners are at the forefront of cell therapy program development, with more late-stage programs than ever before, including two pivotal trials that could result in approvals as early as next year. Our enterprise pharma partnership is off to a strong start and represents an exciting opportunity to support its advancing cell therapy pipeline. Together, with building adoption in early research, we now have a broad set of solutions at every stage, from discovery through commercialization. We believe we have strong momentum heading into the end of the year and remain committed to executing on our priorities to drive durable long-term growth.”

Third Quarter Financial Results

Total revenue of $10.2 million in the third quarter of 2026, an increase of 49% over the third quarter of 2025.

	o	Core business revenue of $8.2 million in the third quarter of 2026, an increase of 27% over the third quarter of 2025.
	o	Strategic Platform License (SPL) Program-related revenue was $2.0 million for the third quarter of 2026, compared to $0.4 million in the third quarter of 2025.

	·	Gross profit for the third quarter of 2026 was $8.5 million (83% gross margin), compared to $5.2 million (77% gross margin) in the third quarter of 2025.
	·	Non-GAAP adjusted gross margin was 80% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 81% in the third quarter of 2025.
	·	Operating expenses for the third quarter of 2026 were $14.5 million, compared to operating expenses of $19.4 million in the third quarter of 2025.
	·	Third quarter 2026 net loss was $4.8 million compared to net loss of $12.4 million for the same period in 2025.
	·	EBITDA, a non-GAAP measure, was a loss of $5.1 million for the third quarter of 2026, compared to a loss of $13.1 million for the third quarter of 2025; stock-based compensation expense was $1.0 million in the third quarter of 2026 compared to $2.0 million in the third quarter of 2025.
	·	Total SPL agreements was 28 as of September 30, 2026, which includes 13 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.
	·	Total cash, cash equivalents and investments were $132.7 million as of September 30, 2026.

Full Year 2026 Guidance

Excluding the impact of the Akron acquisition, full year revenue is now expected to be at least $34.5 million, consisting of:

Core revenue of approximately $28 million.

SPL Program-related revenue of at least $6.5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and at least $2.5 million from commercial royalties.

Assuming the close of the Akron acquisition, MaxCyte expects to have approximately $40.0 to $45.0 million in total cash, cash equivalents and investments as of the end of 2026, which accounts for an estimated $105.0 million paid in cash and acquisition deal expenses, along with $22.0 million drawn under the MidCap Financial credit facility financing.

On a pro forma basis, excluding the impact of the Akron acquisition and deal-related expenses and other costs related to the Akron acquisition, MaxCyte now expects to end 2026 with approximately $133 million in total cash, cash equivalents and investments, reflecting higher expected revenues and continued management of expenses.

The pro forma amount above is presented solely to provide a comparison, on a consistent basis, to the $132.7 million of total cash, cash equivalents and investments as of September 30, 2026. Because it excludes the cash purchase price, deal-related expenses and other costs related to the Akron acquisition, it is not a forecast of the Company’s actual year-end cash position, and the Company does not expect to hold approximately $133 million of total cash, cash equivalents and investments as of December 31, 2026.

The following tables provide details regarding the sources of our revenue for the periods presented.

	Three Months Ended
	September 30 (Unaudited)
	2026		2025		%
(in thousands, except percentages)
Instruments	$	2,779	$	1,376		102	%
PAs and Consumables		3,092		2,577		20	%
Licenses		1,967		1,803		9	%
Assay Service		43		248		(83	)%
Other		276		402		(31	)%
Total Core Revenue	$	8,157	$	6,406		27	%
Milestones		1,004		254		295	%
Royalties		991		169		486	%
Total Revenue	$	10,152	$	6,829		49	%

Webcast and Conference Call Details

MaxCyte will host a conference call today, November 10, 2026, at 8:30 a.m. Eastern Time. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/. You can access the conference call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S. The conference ID is 1965284.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

Non-GAAP Financial Measures

This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The Company's management uses these non-GAAP measures to compare the Company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.

Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents these Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of net loss, the most comparable GAAP financial measure, to EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the Company's business.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading "Risk Factors" and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue and cash guidance, expectations regarding core business revenue growth in the second half of 2026, the proposed acquisition of Akron Bio, the benefits of the Akron acquisition, including the revenue base assumptions, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.

Risks and uncertainties related to the proposed acquisition of Akron Bio include, but are not limited to, the possibility that various conditions to the consummation of the proposed transaction may not be satisfied or waived; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; that the acquisition may not close on the expected timeline or at all; the significant costs of the acquisition, which have reduced our cash resources and increased our fixed obligations, including $20.0 million of guaranteed deferred payments; dilution to our stockholders from issued shares of common stock; our ability to integrate Akron Bio and realize the anticipated benefits of the acquisition; and risks related to our new indebtedness under our credit facility, including our debt service obligations. These and other risks and uncertainties are described in greater detail in Item 1A, entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

Erik Abdow

ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060

MaxCyte, Inc.

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	September 30,			December 31,
	2026			2025
Assets
Current assets:
Cash and cash equivalents	$	13,372		$	20,065
Short-term investments, at amortized cost		87,908			82,979
Accounts receivable, net		12,054			3,503
Inventory, net		7,380			7,547
Prepaid expenses and other current assets		3,777			4,275
Assets held for sale		180			—
Total current assets		124,671			118,369

Investments, non-current, at amortized cost		31,469			52,570
Property and equipment, net		14,342			17,531
Right-of-use asset - operating leases		10,237			10,920
Intangible assets, net		749			650
Other assets		1,015			2,467
Total assets	$	182,483		$	202,507

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,026		$	1,401
Accrued expenses and other		5,937			7,812
Operating lease liability, current		1,565			1,456
Deferred revenue, current portion		7,388			3,598
Total current liabilities		15,916			14,267

Operating lease liability, net of current portion		15,325			16,487
Other liabilities		311			263
Total liabilities		31,552			31,017

Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2026 and December 31, 2025					—
Common stock, $0.01 par value; 400,000,000 shares authorized, 107,493,772 and 106,789,618 shares issued, and 103,233,238 and 106,789,618 outstanding at September 30, 2026 and December 31, 2025, respectively		1,075			1,068
Additional paid-in capital		435,225			431,905
Treasury stock, 4,260,534 shares, at cost		(5,500	)		—
Accumulated deficit		(279,869	)		(261,483	)
Total stockholders’ equity		150,931			171,490
Total liabilities and stockholders’ equity	$	182,483		$	202,507

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Revenue	$	10,152		$	6,829		$	27,074		$	25,726
Cost of goods sold		1,684			1,596			4,928			4,612
Gross profit		8,468			5,233			22,146			21,114

Operating expenses:
Research and development		2,874			5,316			10,984			17,488
Sales and marketing		4,214			3,936			11,006			15,420
General and administrative		6,553			6,028			19,777			22,634
Restructuring expense		-			3,058			-			3,058
Depreciation and amortization		868			1,044			2,837			3,185
Total operating expenses		14,509			19,382			44,604			61,785
Operating loss		(6,041	)		(14,149	)		(22,458	)		(40,671	)

Other income:
Interest income		1,279			1,733			4,072			5,637
Total other income		1,279			1,733			4,072			5,637
Loss before income taxes		(4,762	)		(12,416	)		(18,386	)		(35,034	)
Provision for income taxes		—			—			—			—
Net loss		(4,762	)		(12,416	)		(18,386	)		(35,034	)
Other comprehensive income		—			—			—			—
Comprehensive loss	$	(4,762	)	$	(12,416	)	$	(18,386	)	$	(35,034	)
Basic and diluted net loss per share	$	(0.05	)	$	(0.12	)	$	(0.17	)	$	(0.33	)
Weighted-average shares outstanding, basic and diluted		103,537,926			106,613,075			105,732,991			106,324,792

MaxCyte, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

	Nine Months Ended September 30,
	2026			2025
Cash flows from operating activities:
Net loss	$	(18,386	)	$	(35,034	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,925			3,268
Impairment of fixed assets		630			—
Lease right-of-use asset amortization		683			587
Net book value of consigned equipment sold		105			70
Loss on disposal of property and equipment		23			132
Stock-based compensation		3,264			8,507
Credit loss expense		—			29
Provision for inventory reserve		400			525
Amortization of discounts on investments		(1,251	)		(2,219	)

Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable		(8,551	)		(3,649	)
Inventory		(708	)		647
Prepaid expense and other current assets		498			744
Other assets		1,464			(924	)
Accounts payable, accrued expenses and other		(2,217	)		(3,338	)
Operating lease liability		(1,053	)		(939	)
Deferred revenue		3,790			(80	)
Other liabilities		48			(47	)
Net cash used in operating activities		(18,336	)		(31,721	)

Cash flows from investing activities:
Purchases of investments		(55,113	)		(98,031	)
Maturities of investments		72,536			117,600
Purchases of property and equipment		(193	)		(1,537	)
Acquisition of intangible assets		(150	)		—
Acquisition of business, net of cash acquired of $541		—			(1,773	)
Net cash provided by investing activities		17,080			16,259

Cash flows from financing activities:
Proceeds from exercise of stock options		29			417
Proceeds from issuance of common stock under employee stock purchase plan		34			134
Repurchases of common stock		(5,500	)		—
Net cash (used in) provided by financing activities		(5,437	)		551
Net decrease in cash and cash equivalents		(6,693	)		(14,911	)
Cash and cash equivalents, beginning of period		20,065			27,884
Cash and cash equivalents, end of period	$	13,372		$	12,973

Unaudited Reconciliation of Net Loss to EBITDA

(in thousands)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Net loss	$	(4,762	)	$	(12,416	)	$	(18,386	)	$	(35,034	)
Depreciation and amortization expense		900			1,072			2,925			3,268
Interest income		(1,279	)		(1,733	)		(4,072	)		(5,637	)
Income taxes		—			—			—			—
EBITDA	$	(5,141	)	$	(13,077	)	$	(19,533	)	$	(37,403	)

Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin

(in thousands, except for percentages)

(Unaudited)

	Three months ended September 30, 2026									Three months ended September 30, 2025
	GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP
Revenue	$	10,152		$	(1,995	)	$	8,157		$	6,829		$	(423	)	$	6,406
Cost of Goods Sold		1,684			(21	)		1,663			1,596			(360	)		1,236
Gross Margin	$	8,468		$	(1,974	)	$	6,494		$	5,233		$	(63	)	$	5,170
Gross Margin %		83	%					80	%		77	%					81	%

	Nine months ended September 30, 2026									Nine months ended September 30, 2025
	GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP
Revenue	$	27,074		$	(6,197	)	$	20,877		$	25,726		$	(2,878	)	$	22,848
Cost of Goods Sold		4,928			(400	)		4,528			4,612			(525	)		4,087
Gross Margin	$	22,146		$	(5,797	)	$	16,349		$	21,114		$	(2,353	)	$	18,761
Gross Margin %		82	%					78	%		82	%					82	%

(1)

Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold.

Exhibit 99.2

MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base

Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials

Expands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially approved therapies

Akron Bio is expected to generate approximately $28 million in revenue and $7-8 million in EBITDA in 2026, with positive cash flow

MaxCyte expects the transaction to nearly double MaxCyte's revenue base, significantly expanding commercial-stage exposure and recurring revenue, and accelerating its path to profitability

MaxCyte secured a new credit facility with MidCap Financial of up to $75.0 million, which, together with existing cash, is expected to fund the combined company through profitability

ROCKVILLE, MD, November 10, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has entered into a definitive agreement to acquire Akron BioProducts LLC (“Akron” or “Akron Bio”) from affiliates of Arcline Investment Management (“Arcline”) for total consideration of $151.8 million. The transaction is expected to close before the end of 2026, subject to customary closing conditions.

Akron, headquartered in Boca Raton, Florida, is a leading supplier of GMP-grade reagents and ancillary materials used throughout the cell therapy manufacturing workflow, including at critical steps before and after cell engineering, including electroporation, from expansion through cryopreservation. Over the past two decades, Akron has built a robust portfolio of ancillary materials designed for cell therapy manufacturing, pioneering the development of Closed System Solutions (CSS)® to streamline production and providing the regulatory support required to enable clinical and commercial programs globally. Like MaxCyte, Akron’s products become embedded in customers’ validated manufacturing processes and regulatory submissions, supported by drug master files (DMFs) referenced in INDs and BLAs, strengthening long-term customer relationships.

“The acquisition of Akron marks an exciting new chapter for MaxCyte,” said Maher Masoud, President and Chief Executive Officer of MaxCyte. “This acquisition represents a significant step forward for us, expanding our presence across the viral and non-viral cell therapy development and manufacturing workflow, while projecting to nearly double our revenue base and accelerate our path to profitability. From day one, Akron provides us with an established portfolio of clinical and commercial programs supported by Akron’s DMFs and reagents. By bringing together two highly complementary businesses, we are diversifying our revenue base, increasing our mix of recurring revenue and expanding our exposure to the growth of commercially approved cell therapies, positioning MaxCyte for more durable near- and long-term growth. Like MaxCyte, Akron has become a trusted supplier to leading biopharma companies by delivering differentiated, high-quality products and best-in-class service. Akron is a market leader in the mission-critical consumables required for cell therapy manufacturing, including cytokines, growth factors, human plasma-derived products and media. We are excited to work alongside the talented Akron team as we bring together two companies to deepen customer relationships and better support cell therapy developers from development through commercialization.”

Strategic and Financial Rationale of the Combination

Adds recurring consumables revenue and commercial-stage exposure: The combination increases MaxCyte’s exposure to recurring revenue tied to commercial-scale manufacturing and deepens relationships with some of the largest biopharmaceutical companies.

Expands MaxCyte’s role across the cell therapy manufacturing workflow and broadens its regulatory footprint: Historically focused on non-viral cell engineering, MaxCyte will expand into the viral ex-vivo cell therapy market through Akron’s products, which are used across multiple cell-engineering methods and at critical steps before and after cell engineering, including electroporation. The combination will be embedded in the workflow of five approved therapies and support over 100 clinical programs, with both companies’ DMFs referenced in customers’ regulatory filings.

Creates cross-selling opportunities and revenue synergies: MaxCyte and Akron have limited customer overlap despite similar call points and end markets, enabling MaxCyte to leverage its existing commercial infrastructure to sell Akron’s products and drive revenue synergies.

Accelerates MaxCyte’s path to profitability: Akron’s positive EBITDA and cash flow are expected to reduce the combined company’s annual cash burn to less than $10 million in 2027, with approximately $40 million to $45 million in cash expected at closing, positioning MaxCyte to reach profitability without fully utilizing its credit facility.

“We are tremendously excited by the opportunity to join these two world-class organizations, leveraging our collective experience and expertise to support our partners as they bring transformative therapies to patients around the world,” said Ezequiel Zylberberg, Chief Operating Officer at Akron Bio. “At Akron, we have always believed in earning our partners’ trust through consistent execution, uncompromising quality, and a deep commitment to the patients they serve. As part of MaxCyte, we remain committed to delivering the quality, reliability, and innovation our partners have come to expect.”

Akron is expected to continue operating under its existing brand, with its leadership team and employees playing an important role in the combined company.

“Akron Bio’s success reflects the dedication of its team, and we believe MaxCyte is the best partner to drive continued growth and expand its impact on patients,” said Arcline. “Our decision to accept MaxCyte shares as part of the consideration reflects our confidence in the combined company’s long-term value and allows us to participate in its future success.”

Transaction Terms

Under the terms of the agreement, MaxCyte will acquire Akron for total consideration of $151.8 million. At the close of the transaction, MaxCyte will pay $105.0 million in cash, subject to customary adjustments, plus 20,639,733 shares of MaxCyte common stock valued at approximately $26.8 million based on the closing price as of November 9, 2026. In addition, MaxCyte will pay $20.0 million in total guaranteed deferred payments, consisting of $10.0 million each, payable on the first business day of January 2028 and January 2029.

MaxCyte will fund the transaction with cash on hand and newly issued MaxCyte common stock. The transaction is not subject to a financing condition or stockholder approval.

Concurrent Financing

In addition, MaxCyte has secured a new credit facility with MidCap Financial of up to $75.0 million, which includes a $55.0 million term loan and a $20.0 million revolving credit facility. At closing, MaxCyte expects to draw $20.0 million under the term loan and $2.0 million under the revolving credit facility. MaxCyte expects these initial drawdowns under the term loan and revolving credit facility, together with cash on hand and the remaining availability under the facility, to fund the combined company’s operations through profitability.

Advisors

Stifel is serving as both exclusive financial advisor and exclusive financing agent, and Sidley Austin LLP is serving as legal counsel, to MaxCyte. Jefferies LLC is serving as exclusive financial advisor, and Bass, Berry & Sims PLC and Fredrikson & Byron, P.A. are serving as legal advisors to Arcline in connection with the transaction.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

About Akron Bio

Akron Bio is a leading provider of critical materials and manufacturing services supporting the development and commercialization of cell and gene therapies. Through its portfolio of cytokines, growth factors, human plasma-derived products, specialty media, and comprehensive manufacturing services for complex and specialized reagents, Akron empowers therapy developers to advance promising discoveries into scalable, commercial therapies. From early development through commercialization, Akron provides the quality, regulatory support, supply reliability, and manufacturing expertise its partners need to advance therapies with confidence and ultimately serve patients with critical unmet needs. For more information, please visit www.akronbiotech.com.

About Arcline Investment Management

Arcline Investment Management is a private investment firm with over $30 billion in assets under management. Arcline seeks to build the next generation of Industrial Compounders – market-leading, mission-critical industrial platforms designed to consistently compound earnings over decades. For more information, visit www.arcline.com.

About MidCap Financial

MidCap Financial is a middle-market focused, specialty finance firm that provides senior debt solutions to companies across all industries. As of September 30, 2026, MidCap Financial provides administrative or other services for approximately $68 billion of commitments*. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, Inc., pursuant to an investment management agreement. Apollo had assets under management of approximately $1.07 trillion as of September 30, 2026.

For more information about MidCap Financial, please visit www.midcapfinancial.com. For more information about Apollo, please visit www.apollo.com.

*Including $7.5 billion of commitments managed by MidCap Financial Services Capital Management LLC, a registered investment adviser, as reported under Item 5.F on Part 1 of its Form ADV.

Non-GAAP Financial Measures

This press release contains projected EBITDA for Akron, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors in evaluating the operating performance and expected contribution of the Akron business. MaxCyte’s management uses this non-GAAP measure in evaluating the transaction and for budgeting and planning purposes. MaxCyte believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading "Risk Factors" and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue and cash guidance, the proposed acquisition of Akron Bio, the benefits of the Akron Bio acquisition, including the revenue base assumptions, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); the timing and amount of any share repurchases under our share repurchase program; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.

Risks and uncertainties related to the proposed acquisition of Akron Bio include, but are not limited to, the possibility that various conditions to the consummation of the proposed transaction may not be satisfied or waived; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; that the acquisition may not close on the expected timeline or at all; the significant costs of the acquisition, which may reduce our cash resources and increase our fixed obligations, including $20.0 million of guaranteed deferred payments; dilution to our stockholders from the issuance of shares of common stock; our ability to integrate Akron Bio and realize the anticipated benefits of the acquisition; and risks related to our new indebtedness under our credit facility, including our debt service obligations. These and other risks and uncertainties are described in greater detail in Item 1A, entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of this press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:

Investor Relations Contact

Gilmartin Group

Erik Abdow

ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060

Akron Contact

Akron Bio Media Relations

brichardson@akronbiotech.com

Exhibit 99.3

Forward-Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding our expected potential future revenue, the proposed acquisition of Akron Bio (including its expected timing of closing, financing and anticipated benefits), Akron Bio’s expected financial performance, and our expected cash resources and path to profitability. These statements about us and our industry involve substantial known and unknown risk, uncertainties and assumptions, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this Presentation are forward-looking statements. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Presentation, including, without limitation, statements regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Risks and uncertainties related to the proposed acquisition include the possibility that the acquisition does not close on the expected timeline or at all, our ability to integrate Akron Bio and realize the anticipated benefits of the acquisition, and our indebtedness and obligations under the new credit facility. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10- K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available, without charge, on the Securities and Exchange Commission website and through the Investor Menu, Financials section under "SEC filings" on the Investors page of our website at http://investors.maxcyte.com. No statement in this Presentation is intended to be, or intended to be construed as, a profit forecast or profit estimate or to be interpreted to mean that earnings per Company share for the current or future financial years will necessarily match or exceed the historical earnings per Company share. As a result, no undue reliance should be placed on such statements. Any forward-looking statements represent our views only as of the date of this Presentation and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. This Presentation contains EBITDA, which is a non-GAAP measure defined as earnings before interest, taxes, depreciation, and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses these non-GAAP measures to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making. This Presentation also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability. Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of Gross Margin, the most comparable GAAP financial measure to Non-GAAP Gross Margin, is included in the appendix of this Presentation. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate its business.

3 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte Continues to Strengthen Operationally and Financially ✓ Delivered a strong third quarter as MaxCyte continues to execute – Total revenue of $10.2M (+49% YoY); core revenue of $8.2M (+27% YoY) – PA revenue +20% YoY; gross margin of 83% (80% non-GAAP adjusted(1)) – Operating expenses in Q3 down ~25% YoY, cutting net loss by nearly half vs. the same period in 2025 ✓ Raised 2026 total revenue guidance to at least $34.5M – Reflects a return to growth for FY’26 and 15% YoY growth in H2’26 for core revenue – Increased contribution from SPL partners in FY’26 driving growth ✓ Strong balance sheet position with $132.7M in cash(2) – Anticipate ending 2026 with approximately $133.0M of cash, excluding the impact of the acquisition and deal-related expenses (1) Non-GAAP adjusted gross margin excludes inventory provisions and SPL program-related revenue. (2) Cash, cash equivalents and investments as of September 30, 2026.

4 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing Deal Overview ACQUISITION DETAILS ✓ Following a competitive process, we have signed a definitive agreement to acquire Akron Bio from Arcline ✓ Akron attracted multiple interested parties; MaxCyte was selected based on strong strategic fit ✓ Total consideration of ~$151.8M, consisting of $105.0M cash upfront, 20.6M MaxCyte shares (~$26.8M(1)) and $20.0M of guaranteed deferred payments in 2028 & 2029 ✓ MaxCyte will fund the transaction with cash on hand and newly issued common stock ✓ Arcline’s election to take MaxCyte shares signals its confidence in the combined company’s potential ✓ Expected to close before year-end 2026, subject to customary closing conditions; not subject to a financing condition or stockholder approval FINANCING DETAILS ✓ Secured credit facility with MidCap Financial of up to $75.0M, consisting of a $55.0M term loan and $20.0M revolving credit facility ✓ Expect to draw $20.0M of the term loan and $2.0M of the revolver at closing ✓ MaxCyte expects to achieve profitability without fully utilizing the credit facility ✓ With an expected cash balance of approximately $40 million to $45 million upon closing and anticipated pro forma annual cash burn of less than $10 million in 2027, MaxCyte expects to reach profitability without fully utilizing its credit facility ✓ Expected to close concurrent with the acquisition of Akron Bio before year-end 2026 Credit facility, together with cash on hand, expected to be sufficient to fund the business through profitability A leading supplier of GMP-grade reagents and ancillary materials used before and after cell engineering, including electroporation (1) Based on the closing price of MaxCyte common stock as of November 9, 2026.

© 2026 MaxCyte, Inc. All Rights Reserved 5 Why Akron Bio: Four Ways the Combination Creates Value Strengthened Leadership in Cell Therapy 3x MaxCyte triples its commercial & registrational programs ( 4 → 12), including 5 approved therapies Cross-Selling Opportunity 2x Addressable program base, with Akron products used before and after cell engineering, including electroporation Compelling Financial Profile, Funded to Profitability ~2x Revenue base, with the business funded through profitability Broader Market, Workflow & Regulatory Footprint ~10% Customers shared today, leaving room to sell both portfolios across the base A strategic one-step adjacency in the high-growth bioprocessing ecosystem – the combined company benefits from:

6 © 2026 MaxCyte, Inc. All Rights Reserved Akron Bio is a Leading Supplier of Critical Cell Therapy Inputs Headquartered in Boca Raton, FL Founded in 2006 cGMP production facility and support from a network of global cGMP contract manufacturing partners Revenue ($M)(2) Akron Highlights ✓ Mission-critical supplier of GMP-grade reagents and ancillary materials used before and after cell engineering, including electroporation in cell therapy production. ✓ Like MaxCyte, Akron’s products are spec’d into customers’ validated processes, referenced in IND / BLA submissions ✓ Spec’d into 4 commercially approved therapies and 4 registrational-stage programs, as well as 85+ additional clinical programs ✓ Akron brings revenue scale and positive EBITDA that accelerate MaxCyte’s path to profitability ✓ Akron wins on quality, service and innovative proprietary packaging. (1) Subject to customary closing conditions; no MaxCyte stockholder vote required. (2) 2026 revenue and EBITDA estimates based on Management’s expectations, EBITDA is a forward-looking non-GAAP measure (3) Based on Akron FY2018 to FY2025 actuals. (4) Source: DeciBio Estimates Akron At A Glance AKRON PRODUCTS SPAN THE CELL THERAPY WORKFLOW AKRON’S STRONG FINANCIAL FOOTPRINT 80-85% Revenue from Spec’d-in Customers (3) 40-45% Revenue from Commercial-stage Customers(3) Activation & Culture Genetic Modification Expansion Formulation & Cryopreservation ▪ IL-2, IL-7, IL-15 ▪ Human AB Serum ▪ Culture Media ▪ GMP fibronectin (viral transduction) ▪ IL-2, IL-7, IL-15, IL-21 ▪ Human AB Serum ▪ GMP fibronectin ▪ Human Serum Albumin ▪ CryoSolve® cryomedia $7M-$8M FY2026 Expected EBITDA(2) Low-to-Mid-Teens Revenue Growth Expected in 2027, with Potential for Longer-Term Acceleration as Commercial Programs Scale $21M Mid 60s Gross Margin Profile(3) $23M $28M 2025A 2026E Low-to- Mid-Teens Revenue CAGR (2018 to 2025)(3)

© 2026 MaxCyte, Inc. All Rights Reserved 7 Process Development Cell Isolation & Expansion Cell Culture Cell Engineering Cell Expansion Cryopreservation USED BEFORE CELL ENGINEERING USED AFTER CELL ENGINEERING Expanding Our Footprint Across the Cell Therapy Workflow and Developers’ Regulatory Packages WORKFLOW INTEGRATION More products incorporated across the cell manufacturing process REGULATORY INTEGRATION MaxCyte and Akron Drug Master Files referenced within IND / BLA submissions DMF MaxCyte and Akron Are Embedded Across Complementary Steps of the Cell Therapy Workflow Viral Delivery Non-Viral Delivery electroporation

8 © 2026 MaxCyte, Inc. All Rights Reserved Expanded Portfolio Covers the Development Lifecycle, Pairing MaxCyte’s Platform Economics With Akron Bio’s Recurring Consumables Razor/Razor Blade Economics Full scale RUO Instrument Sale Annual License Fee Razor/Razor Blade Economics + Share of Therapeutic Economics Clinical Milestones and Commercial Royalties/Sales Based Payments Single-use Disposables (PAs) Full scale GMP Single-use Disposables (PAs) + + + Cytokines Growth Factors Human Plasma-Derived Products Media & Supplements Recurring Consumables Academic Preclinical Clinical Commercial 80-85% from Spec’d-in Customers

© 2026 MaxCyte, Inc. All Rights Reserved 9 1 MaxCyte +4 Akron 5 Commercial Programs +3 MaxCyte Registrational Programs +4 Akron Registrational Programs 12 Commercial + Registrational Programs Broader portfolio with multiple near-term commercialization opportunities Established Commercial Base MaxCyte Registrational Programs Akron Registrational Programs Expanded Portfolio Registrational programs: potential commercialization 2027E–2028E 95+ EARLIER STAGE DEVELOPMENT PROGRAMS ACROSS THE COMBINED PORTFOLIO Broad development-stage base supporting future commercial opportunities Broad Combined Clinical Portfolio Underpins 12 Commercial and Registrational-Stage Programs 3x Akron triples MaxCyte’s commercial & registrational programs (4 → 12)

© 2026 MaxCyte, Inc. All Rights Reserved 10 Akron Bio More Than Doubles Our Addressable Program Base within the Growing Cell Therapy Market ~770 ~360 Combined company MaxCyte today Attractive & Growing Cell Therapy Market Worldwide Commercial Cell Therapy Revenue Forecast ($B)(1) Addressable Ex Vivo Cell & Gene Therapy Programs Number of programs our products can serve, U.S. and Europe(2) Primarily non-viral programs Akron unlocks access to cell therapy programs regardless of engineering method Akron Bio more than doubles our addressable program base Combined company positioned to benefit from underlying market growth and increasing exposure to faster-growing commercial-scale manufacturing (1) Evaluate Pharma and DeciBio (2) MaxCyte tracking of ex vivo cell and gene therapy programs: roughly 360 of approximately 770 programs primarily served by MaxCyte’s electroporation platform today. Strong efficacy driving adoption and approvals Robust commercial outlook Sizable clinical pipeline Global approvals and expanded indications Favorable regulatory momentum Market Growth Drivers Broader cell-specific reagent selection Earlier GMP-grade reagent adoption Underlying CGT Reagents Market Growth $1.6B $2.9B 2025 2030 13% CAGR Commercial Cell Therapy Sales Growth $7B $19B 2025 2030 23% CAGR Attractive & Growing Cell Therapy Market Worldwide market forecasts, 2025 - 2030(1) Combined company positioned to benefit from underlying market growth and increasing exposure to faster-growing commercial-scale manufacturing 23% CAGR 2x

© 2026 MaxCyte, Inc. All Rights Reserved 11 MaxCyte 2.0 - Akron Bio Strengthens Our Growth Story and Accelerates Our Path to Profitability Strengthened Leadership in Cell Therapy ✓ Triples commercial & registrational programs to 12 including 5 commercial therapies ✓ Spec’d into 100+ clinical cell therapy programs (85+ from Akron) ✓ 74% recurring revenue and 30% of revenue tied to commercial assets ✓ Increased exposure to some of the largest biopharma companies Cross-Selling Opportunity ✓ Doubles MaxCyte’s addressable program base, across both viral & non-viral ex vivo programs ✓ Unlocks exposure across the Cell Therapy manufacturing continuum ✓ Expands regulatory footprint with combined DMFs referenced over 300 times in regulatory filings, including IND/ BLA submissions. Compelling Financial Profile, Funded to Profitability Broader Market, Workflow & Regulatory Footprint ✓ Minimal number of shared customers today (~10%), despite similar call points and end markets ✓ Deepens relationships with existing and new customer base A strategic one-step adjacency in the high-growth bioprocessing ecosystem – the combined company benefits from: The Combined Company: broader scale, lower customer concentration, more recurring and commercial revenue 14% Largest customer share of combined revenue (vs. 27% MaxCyte standalone)(1) 57%→74% Recurring revenue mix, MaxCyte standalone to combined(1)(2) ~30% Combined revenue from commercial-stage customers(1) 100+ Clinical stage programs across combined portfolio 2026 Vertex: $9.344M 2026 MXCT Rev: $34.761M 2026 Akron Rev: $30.117M Source: Management projections. (1) Reflects management projections for MaxCyte and Akron for FY’26 (2) Recurring revenue defined as revenue from spec’d-in programs, for Akron and revenue from Licenses, PAs and Royalties, for MaxCyte. This is based on 2026 projections ✓ ~Doubles MaxCyte’s revenue base, accelerating the path to profitability ✓ Best-in-class margin profile with positive EBITDA and cash flow ✓ Significantly reduces cash burn from ~$17M in 2026 to <$10M in 2027 ✓ $40M–$45M cash at closing alongside MidCap Financial facility funds path through profitability

All other trademarks are the property of their respective owners. ©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks. Thank you! Any Questions? ir@maxcyte.com 12 © 2026 MaxCyte, Inc. All Rights Reserved

14 © 2026 MaxCyte, Inc. All Rights Reserved Discovery / R&D Preclinical Early-Stage Trials Late-Stage Trials Launched Akron Bio interception point Process development Clinical and commercial GMP manufacturing RUO- / GMP-grade GMP-grade Ancillary inputs may be interchanged as customers define workflow processes, with cost a primary driver of choice Limited Process Spec-in First-Gen Spec-in Second-Gen Spec-in Switching may require limited bridging studies but is still possible, e.g., to support step-changes in scale Switching ancillary inputs requires extensive bridging studies and is done only as a last resort for major manufacturing issues Once spec’d in, Akron’s inputs become increasingly difficult to switch as programs advance Recurring supply tied to commercial-scale manufacturing ~10x increase in average annual spend from late-stage Preclinical to Phase III Illustrative Step-Ups in Revenue to Akron Along the Development Cycle Akron Bio Supplements MaxCyte’s Already Durable, Recurring Revenue Model

Exhibit 99.4

Forward Looking Statement Disclaimer 2 © 2026 MaxCyte, Inc. All Rights Reserved Certain statements in this document (this “Presentation”) are, or may be deemed to be, forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding our expected potential future revenue. These statements about us and our industry involve substantial known and unknown risk, uncertainties and assumptions, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this Presentation are forward-looking statements. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Presentation, including, without limitation, statements regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available, without charge, on the Securities and Exchange Commission website and through the Investor Menu, Financials section under "SEC filings" on the Investors page of our website at http://investors.maxcyte.com. No statement in this Presentation is intended to be, or intended to be construed as, a profit forecast or profit estimate or to be interpreted to mean that earnings per Company share for the current or future financial years will necessarily match or exceed the historical earnings per Company share. As a result, no undue reliance should be placed on such statements. Any forward-looking statements represent our views only as of the date of this Presentation and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. This Presentation contains EBITDA, which is a non-GAAP measure defined as earnings before interest, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses these non-GAAP measures to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making. This Presentation also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability. Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of Gross Margin, the most comparable GAAP financial measure to Non-GAAP Gross Margin, is included in the appendix of this Presentation. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate its business.

MaxCyte at a Glance 3 © 2026 MaxCyte, Inc. All Rights Reserved Our Mission We power the future of cell and gene therapy with innovative, scalable cell engineering solutions that enable our customers to deliver advanced therapies to patients Base-editing (CRISPR), CRISPR, ARCUS, RNA-Based Engineering, TALENS, Zinc Finger Nucleases (ZFNs) 14 Clinical and Commercial Therapies Supported 2025 Revenue • Genetic diseases, solid tumors, infectious disease, Hematological • Malignancies, autoimmune disease 28 SPL Customers + 1 Multi-Platform License Agreement $133M Cash & Cash Equivalents1 $33.0M 2025 Non-GAAP Adjusted Gross Margins 81% 2 1. As of September 30, 2026 2. Excluding SPL Program-related revenue and reserves for excess and obsolete inventory. See appendix for reconciliation to GAAP gross margins

Cell and Gene Therapy Development 4 © 2026 MaxCyte, Inc. All Rights Reserved Cell Engineering (Electroporation) Cell Proliferation In-Vivo Ex-Vivo Viral/Non-Viral Vector for delivery to Specific Organ Tissue The engineering of cells to develop therapies addressing a host of human diseases with unmet medical needs Cells Collected from Universal Donor or Patient Personalized Therapy Cryopreservation Patient Cell & Gene Therapy is one of the fastest growing and most promising treatment modalities ~2,130 active clinical trials focused on as of Dec 2025* Aggregate of $11.1B raised in 2025* Genetic diseases, solid tumors, infectious disease, hematological, and autoimmune 50 approved cell and gene therapies** *Alliance for Regenerative Medicine (“ARM”) as of Dec 2025 **FDA approved Cellular and Gene Therapy Products

Addressing the Challenges of Cell & Gene Therapy Development 5 © 2026 MaxCyte, Inc. All Rights Reserved Next-generation cell therapy programs have become increasingly complex requiring multiple edits Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster Lack of industry standard for cell engineering process development causes costly and inconsistent manufacturing runs Many steps in the cell engineering process with lack of support or safety assessments before regulatory review

Large Opportunity in Ex-Vivo Cell and Gene Therapy 6 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte # of Potential SPLs Research & Discovery Pre-Clinical Clinical Commercial 124 Programs 82 Non-Viral Programs (66%) 383 Programs 193 Non-Viral Programs (50%) 249 Programs 84 Non-Viral Programs (34%) 10 Programs 1 Non-Viral Program (10%) Ex-Vivo Cell & Gene Therapy TAM 201 Ex-Vivo Cell & Gene Therapy Biotechs 83 Non-Viral Ex-Vivo Cell & Gene Therapy Biotechs Gene Editing Tools: • ARCUS • Base-editing (CRISPR) • Prime-editing (CRISPR) • CRISPR • RNA-Based Engineering • Transposon • TALENS • Zinc Finger Nucleases (ZFNs) Source: MaxCyte Company Estimates for U.S. and EU Markets Programs with undisclosed vector are assumed to be Viral and Non-Viral at the market concentration ratio of 53% to 47%, respectively

The Expert Platform Enabling Non-Viral Cell Engineering 7 © 2026 MaxCyte, Inc. All Rights Reserved Full scale RUO Small/mid-scale RUO Large Scale RUO/cGMP Full scale RUO/cGMP 75 thousand to 700 million cells 75 thousand to 20 billion cells 5 billion to 200 billion cells 75 thousand to 20 billion cells High Performance • >90% transfection efficiencies (depending on cell type and molecule) • >90% cell viabilities • Computer-controlled system for reproducible results Flexibility • Single, fully-defined, animal component-free electroporation buffer for all cell types • Pre-loaded library of validated, cell-specific protocols Scalability – Ability to Transfect • 75,000 to 7 million cells in seconds • Up to 20 billion cells in less than 30 minutes • And up to 200 billion cells in less than 30 minutes with the high scale VLx High Quality • Sterile, single-use processing assemblies (PAs) • Closed, cGMP-compliant, ISO-certified, and CE marked instruments • Supported by US FDA Master File and global equivalents Key Applications: Ex-Vivo Engineered Cell Therapies Customer Base: Leading global cell therapy developers and academic translational centers Additional Electroporation Applications in Drug Discovery Viral Vector Production – Transfect adherent or suspension cells to produce a variety of viral vectors. Cell Based Assays – Produce assay-ready cells faster with scalable electroporation. Gene Editing – Navigate the complexities of genome engineering with highly efficient delivery. Antibody & Protein Production – Accelerate biotherapeutic development with transient expression for gram-scale protein production. Vaccine Development – Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles and more. Research & discovery 96-well platform RUO 100 thousand to 10 million cells Launched Q1-26

Instrument purchase & research scale GMP: 25µL – 100mL on GTx 21 CFR Part 11 Compliant MaxCyte’s Solutions Span Cell & Gene Engineering 8 © 2026 MaxCyte, Inc. All Rights Reserved Industry-leading, scalable Expert Electroporation Platform and best-in-class customer support Commercial Strategic platform license for clinical & commercial manufacturing IND-enabling lease Discovery Process Development IND-enabling activities IND-enabling study / Clinical IND filing BLA filing Instrument purchase & full scale with flow EP RUO RUO GMP GMP Screening Validation Lead ID Concept Discovery Optimization Verification RUO: 25µL – 3.5mL on DTx RUO: 25µL – 3.5mL on ATx RUO: 25µL – 100mL on STx Strategic platform license for large allogeneic manufacturing GMP: 25µL – 1L on VLx 21 CFR Part 11 Compliant GMP

MaxCyte’s Flow Electroporation® technology integrates efficiently within a closed cGMP cell therapy workflow 9 © 2026 MaxCyte, Inc. All Rights Reserved Cell Isolation & Expansion CCBE Electroporation Cell Expansion Cryopreservation Add loading agent (mRNA, pDNA, RNP…) and Electroporate Process cells on different platforms Wash media and exchange from different platforms to MaxCyte Buffer Infusion and cryopreservation Seamlessly scale from initial cell therapy concept to commercialization • Leverages the reversible permeability of the cell membrane in response to an electric charge • Universally delivers molecules, such as nucleic acids, gene-editing tools and proteins, into cells • Agnostic to cell type, approach (auto/allo) and/or gene manipulation technology • Supported by a robust intellectual property portfolio (200+ patents granted in US and foreign jurisdictions and 100+ patents pending worldwide) • Enables customers to use a single platform from concept through to the clinic in a GMP environment • >100 protocols optimized through 25 years of research by experts in biophysics, biochemistry and cell biology

Development of Ex Vivo Cell Therapies Requires Highly Specialized Engineering Tools and Assays 10 © 2026 MaxCyte, Inc. All Rights Reserved Lentivirus Adeno-associated virus Lipid nanoparticles Electroporation Engineering Tools Delivery Technologies CRISPR/Cas gene editing Transposase integration mRNA transient expression Stable DNA transduction Engineered Cell Therapy Starting Cell Material Post-engineering analyses: • On-target editing confirmation • Off-target editing risk assessment • Cell functional assays • Cell phenotype characterization Engineering Strategies Pre-engineering analyses: • Cell health determination • Cell purity characterization • Cell identity confirmation ✓ Single alteration vs. multiple alterations ✓ Sequential engineering vs. simultaneous engineering ✓ Integrating vs. non-integrating approaches Developing engineering ex vivo cell therapies is highly complex

MaxCyte’s Solutions are Uniquely Positioned to Support Cell Therapy Development 11 © 2026 MaxCyte, Inc. All Rights Reserved Flow Electroporation technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches 23+1 Field Application Scientists support our customers in their development process Expert platform provides industry leading transfection efficiency & cell viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production Regulatory Support Superior Results Complex Engineering Optimization Scientific Support FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory review MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes and the ability to seamlessly scale up from pre-IND to the clinic and commercialization 1. As of December 31, 2025

MaxCyte’s Platform Generates Recurring Revenue in Pre-Clinical, Clinical, and Commercial 12 © 2026 MaxCyte, Inc. All Rights Reserved Razor/Razor Blade Economics Full scale RUO Preclinical and Academic Revenue Model Instrument Sale Clinical and Commercial Revenue Model Annual License Fee Razor/Razor Blade Economics + Share of Therapeutic Economics Clinical Milestones and Commercial Royalties/Sales Based Payments Single-use Disposables (PAs) Full scale GMP Single-use Disposables (PAs) + + + MaxCyte captures unique economic participation in customers success as a result of its proven technology and differentiated technical, scientific, and regulatory support

Lyell Immunopharma MaxCyte has an Active Portfolio of SPLs 13 © 2026 MaxCyte, Inc. All Rights Reserved 28 SPL Partners Sana Biotechnology Beam Therapeutics cGMP Compatible Platform FDA Master File and Technical Files Experienced FAS and sales support Leading know-how and engineering process improvement 13 Active Clinical Programs Represents ~$105M of precommercial milestone potential >$30M of milestone payments to date through SPL model ` Updated as of November 2026 1. Editas Medicine, Myeloid, and Vor Biopharma have announced their exit of the ex-vivo space 2. Cleared INDs or Equivalent 6 SPL partners in preclinical 16 preclinical programs 12 SPL partners in clinical 13 clinical programs2 10 SPL partners in research1 1 Commercial Program

Typical MaxCyte SPL Economics 14 © 2026 MaxCyte, Inc. All Rights Reserved Early Clinical: (Phase 1/2) Years 1-3 • Mid 6-figure up to low 7-figure milestones • 1-3+ instruments + disposables Mid-late Clinical: (Phase 2/3) Years 3-5+ • 7-figure milestone • Increasing instrument and disposables usage Approval: Year 5+ • Multiple 7-figure milestones based on geographic region (e.g. US and Europe) Commercial Phase • Royalty and/or sales-based payments • Annual instrument fees and disposable sales Instruments and Processing Assemblies Milestones Royalties & Sales-Based Payments Pre-commercial milestones in early clinical, mid-late clinical and product approval Significant development milestones and high-value participation in future commercial success of partners Recurring revenues from lease of instruments and sales of single-use disposables Royalties and Sales-based payments upon partner’s product commercialization

Differentiated Commercial Relationships Expand Sales Funnel 15 © 2026 MaxCyte, Inc. All Rights Reserved Field Application Scientists (FAS) & Business Managers Highly Technical Employees and Commercial Team Unparalleled scientific support to customers Customer relationships at early stages of cell & gene therapy development Signed SPL *Updated as of December 31, 2025 MaxCyte has a team of 23+ highly trained FAS & business development managers* Global teams providing scientific, technical, and regulatory expertise FAS works with prospective customers to optimize and implement cell engineering methods, processes, and applications MaxCyte grows its sales funnel by leading with scientific, technical, and regulatory expertise 50 Advanced Degrees and 23 PhDs* Support academic and translational institutions, biotech companies, and pharma companies in discovery and pre-clinical

16 © 2026 MaxCyte, Inc. All Rights Reserved As of November 2026 / Includes SPL Programs with multiple Clinical Trials for different indications SPL Portfolio: 15 Active Clinical Trials Partner Program Phase Cell Approach Cell Type Disease Area Vertex Pharmaceuticals CASGEVY Commercial Autologous HSCs Beta-thalassemia Vertex Pharmaceuticals CASGEVY Commercial Autologous HSCs Sickle cell disease AlloTera Sofi-cel Pivotal Allogeneic T-Cells T Cell Malignancies Undisclosed Partner A - Pivotal Undisclosed Undisclosed Undisclosed CRISPR Therapeutics Zugo cel 1/2 Allogeneic T-Cells Hematological Malignancies CRISPR Therapeutics Zugo-cel 1/2 Allogeneic T-Cells Autoimmune Disease Imugene Azer-cel 1/2 Allogeneic T-Cells Hematological Malignancies Kamau Therapeutics Nula-Cel 1/2 Autologous HSCs Sickle Cell Disease KSQ Therapeutics KSQ-001EX 1/2 Autologous TILs Advanced Solid Tumors KSQ Therapeutics KSQ-004EX 1/2 Autologous TILs Advanced Solid Tumors TG Therapeutics Azer-cel 1 Allogeneic T-Cells Multiple Sclerosis Vittoria Biotherapeutics VIPER-101 1 Autologous T-Cells T-Cell Lymphoma Undisclosed Partner B - 1 Undisclosed Undisclosed Undisclosed Undisclosed Partner C - 1 Undisclosed Undisclosed Undisclosed Undisclosed Partner D - 1 Undisclosed Undisclosed Undisclosed

SPL Case Study: CASGEVY® 17 © 2026 MaxCyte, Inc. All Rights Reserved CASGEVY® for Sickle Cell Disease (SCD) and for Transfusion-Dependent Beta-Thalassemia (TDT) (2023 and 2024) 2013 – MaxCyte supports Inception Genomics (Changed name to CRISPR Therapeutics AG in 2014) • Support for programs in research 2018 – Vertex/CRISPR achieves IND Milestone Sept 28, 2022 – MaxCyte Signs SPL with Vertex to advance Exa-cel • Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Expert platform Dec 8, 2023 – FDA Approves CASGEVY® (for treatment of SCD) 2021 – Vertex initiated Pivotal Trial for CASGEVY® Jan 16, 2024 – FDA Approves CASGEVY® (for treatment of TDT) Feb 12, 2024 – European Commission Approves CASGEVY® (for treatment of SCD and TDT) Nov 15, 2023 – UK MHRA Approves CASGEVY® (for treatment of SCD and TDT) CASGEVY® Jan 9, 2024 – SFDA Approves CASGEVY® (for treatment of SCD and TDT)

MaxCyte Supports the Future of Cell & Gene Therapies 18 © 2026 MaxCyte, Inc. All Rights Reserved WAVE 1 1 Approved Product WAVE 2 5 Product Candidates WAVE 3 9 Product Candidates WAVE 4 16 Product Candidates Vertex/ CRISPR CASGEVY® Approved 2023 US FDA, European Commission & Additional Regulatory Bodies Launch Potential: 2027 – 2028 5 products set to enter pivotal studies in next 6 to 18 months Launch Potential: 2028 + 9 products currently in Phase 1 Launch Potential: 2032 + 16 products in preclinical development Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of September 2026 MaxCyte supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential

Genentech Partnership Multi-Platform Technology License Partnership An enterprise-level relationship providing Genentech access to MaxCyte's ExPERT GTx® platform and additional platform technologies across research, clinical development, and commercial manufacturing workflows Enterprise Framework Structured to support Genentech's cell therapy portfolio under a single relationship — not on a product-by-product basis Platform Access ExPERT GTx® plus complementary technologies spanning non-viral cell engineering and analytical assessment Full Lifecycle Integrated support for ex vivo cell engineering from early discovery through cGMP manufacturing Portfolio Scale Enables broad platform adoption across multiple development programs rather than individual assets © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte is Supporting Genentech’s Active Cell & Gene Therapy Portfolio

An Expanding Partnering Model for Large Pharma Enterprise partnerships complement MaxCyte's Strategic Platform License (SPL) model Strategic Platform License (SPL) Product-by-product Non-exclusive license to ExPERTTM platform for biotechs developing individual therapeutic programs An attractive solution for biotechnology customers developing individual programs Annual license fees and milestones in clinical development, plus royalties on net sales at commercialization Enterprise Partnership (Example: Genentech) Portfolio-wide Enterprise-level relationship designed to support a pharma’s cell therapy portfolio (access to EXPERTTM platform & analytical assessment services) An additional commercial model that expands MaxCyte’s addressable market among large pharma organizations © 2026 MaxCyte, Inc. All Rights Reserved Recurring license and platform-access revenue with earlier monetization, milestone opportunities, and risk-adjusted economics comparable to an SPL The enterprise model expands MaxCyte’s commercial toolkit while preserving the value proposition of the existing SPL portfolio

MaxCyte’s Roadmap to Becoming a Premier Cell Engineering Solutions Provider 21 © 2026 MaxCyte, Inc. All Rights Reserved Electroporation technology provider Comprehensive cell engineering solutions Gene Editing Tools Over $1.25b market • Key markets addressed: in vivo and ex vivo cell therapy • Other key markets addressed: Agbio, bioprocessing, research and discovery tools Genetic Payloads (i.e. gene insertion/expression) Over $6.0b market • Key markets addressed: in vivo and ex vivo cell therapy • Other key markets addressed: vaccines, bioprocessing, research and discovery tools Other Biological Delivery Over $4.0b market • Key markets addressed: in vivo and ex vivo cell therapy • Other key markets addressed: vaccines, bioprocessing, research and discovery tools Cell engineering risk assessment Organic and Inorganic Investment • Product Development • Acquisitions • Licensing Deals • Distribution Deals Source: Internal analysis

Editing Assessment Services Strategy 22 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte provides ex-vivo and in-vivo developers with best-in-class on-target and off-target risk assessment services Use Cases: candidate guide screening, guide RNA selection Use Cases: Off-target risk assessment, guide RNA selection, IND filings ✓ Highly sensitive ✓ Universal for all editors ✓ Population-scale variant assessment ✓ Multiple orthogonal methods ✓ Variant effect prediction ✓ GLP-grade Guide Screening ✓ Rapid turnaround time ✓ Comprehensive report ✓ Minimize risk from variation at on-target locus Guide RNA Selection ✓ Low-cost per guide ✓ Evaluate multiple guides ✓ Reduce program risk through early profiling and selection Use Cases: Cellular Editing Assessment, IND filings ✓ Sensitive detection methods ✓ Relevant cell types ✓ On- and off-target analysis ✓ Biologic impact assessment ✓ GLP-grade ✓ Increases program likelihood of success ✓ Decreases risk of unexpected costs or program delays ✓ Aligns with most recent FDA guidance for gene edited therapies ✓ Quicker time to clinic and safer therapies Discovery Pre-Clinical Development and IND-Enabling Studies BENEFITS

23 © 2026 MaxCyte, Inc. All Rights Reserved Financial Summary $1.4 $2.8 $2.6 $3.1 $1.8 $2.0 $0.2 $0.0 $0.4 $0.3 3Q25 3Q26 Core Revenue: +27% Increase $7.1 $6.8 $14.0 $11.9 $10.3 $8.9 $1.1 $1.2 $6.1 $3.4 2024 2025 Core Revenue: (9%) Decline 1. Excluding SPL Program-related revenue and reserves for excess and obsolete inventory. See appendix for reconciliation to GAAP gross margins Financial Highlights (As of September 30, 2026) 80% Non-GAAP adjusted Gross Margin1 41% Core revenue generated from SPL partners as a % of core revenue 936 Total Installed Base of Instruments (sold or licensed) $133 million Total cash, cash equivalents, and investments Total Annual Revenue (millions) Core Revenue Total Quarterly Revenue (millions) Core Revenue $38.6 $33.0 $10.2 $6.8 $0.4 $0.8 $2.0

Financial Summary 24 © 2026 MaxCyte, Inc. All Rights Reserved In millions, except percentages 2024 2025 YTD 2026 Total Core Revenue $32.5 $29.6 $20.9 y/y growth 9% (9%) (9%) SPL-Program Related Revenue $6.1 $3.4 $6.2 y/y growth (47%) (44%) 115% Total Revenue $38.6 $33.0 $27.1 y/y growth (6%) (15%) 5% Gross Profit $31.5 $26.8 $22.1 Gross Margin % 82% 81% 82% Non-GAAP Adjusted Gross Margin %1 84% 81% 78% Operating Expenses $82.7 $78.7 $44.6 Net Income (Loss) ($41.1) ($44.6) ($18.4) EBITDA2 ($47.6) ($46.9) ($19.5) Full Year Ended December 31, 1. Excluding SPL Program-related revenue and reserves for excess and obsolete inventory. See appendix for reconciliation to GAAP gross margins 2. See appendix for Unaudited Reconciliation of Net Loss to EBITDA 9 months

Disciplined Management is Committed to Growth Investment and Efficient Spending 25 © 2026 MaxCyte, Inc. All Rights Reserved MaxCyte is well capitalized and funded to achieve profitability with existing capital Alignment of spending and resources to growth areas Organic investment in new products and product enhancements Reduction of annual cash burn excluding one-time and non-cash items Realize operating leverage on existing cost base Inorganic investment to solve critical pain points in Cell & Gene Therapy Healthy balance sheet ~$133M of cash, cash equivalents, and investments1 1. As of September 30, 2026

All other trademarks are the property of their respective owners. ©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks. Thank you! Any questions? ir@maxcyte.com 26 © 2026 MaxCyte, Inc. All Rights Reserved

Appendix – Historical Core Business Disclosure 27 © 2026 MaxCyte, Inc. All Rights Reserved 3Q'22 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q’24 3Q’24 4Q’24 1Q’25 2Q’25 3Q’25 4Q’25 1Q’26 2Q’26 3Q’26 (in $ thousands) Instrument 2,575 3,705 2,189 2,126 1,672 2,330 1,928 1,762 1,764 1,629 1,444 2,141 1,376 1,841 1,346 1,761 2,779 PAs 4,350 3,721 2,600 3,293 2,226 2,163 3,432 2,974 3,432 4,169 3,871 3,128 2,577 2,312 2,293 2,337 3,092 Licenses 2,736 2,813 2,809 2,667 2,444 2,406 2,604 2,610 2,528 2,554 2,531 2,619 1,803 1,993 2,097 1,822 1,967 Assay service - - - - - - - - - - 142 51 248 335 188 245 43 Other 227 331 174 203 258 263 224 229 416 258 255 259 402 274 294 338 276 Total Core Revenue 9,889 10,570 7,772 8,289 6,600 7,162 8,188 7,575 8,140 8,610 8,243 8,198 6,406 6,755 6,218 6,503 8,157 Installed base of instruments (sold or leased) 575 616 633 654 664 683 708 723 739 760 787 814 830 857 877 899 936 Core Revenue Generated by SPL Clients as a % of Core Revenue 40% 34% 52% 49% 45% 45% 53% 51% 53% 55% 57% 42% 53% 36% 44% 46% 41%

Appendix – Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin 28 © 2026 MaxCyte, Inc. All Rights Reserved 1. Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold. Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted Gross Margin (in thousands, except for percentages) (Unaudited) Three months ended September 30, 2026 Three months ended September 30, 2025 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Revenue $ 10,152 $ (1,995) $ 8,157 $ 6,829 $ (423) $ 6,406 Cost of Goods Sold 1,684 (21) 1,663 1,596 (360) 1,236 Gross Margin $ 8,468 $ (1,974) $ 6,494 $ 5,233 $ (63) $ 5,170 Gross Margin % 83% 80% 77% 81% Nine months ended September 30, 2026 Nine Months ended September 30, 2025 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Revenue $ 27,074 $ (6,197) $ 20,877 $ 25,726 $ (2,878) $ 22,848 Cost of Goods Sold 4,928 (400) 4,528 4,612 (525) 4,087 Gross Margin $ 22,146 $ (5,797) $ 16,349 $ 21,114 $ (2,353) $ 18,761 Gross Margin % 82% 78% 82% 82%

Appendix – Unaudited Reconciliation of Net Loss to EBITDA 29 © 2026 MaxCyte, Inc. All Rights Reserved Unaudited Reconciliation of Net Loss to EBITDA (in thousands) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Net loss $ (4,762) $ (12,416) $ (18,386) $ (35,034) Depreciation and amortization expense 900 1,072 2,925 3,268 Interest income (1,279) (1,733) (4,072) (5,637) Income taxes — — — — EBITDA $ (5,141) $ (13,077) $ (19,533) $ (37,403)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

8 documents

MaxCyte to acquire Akron BioProducts for $152M

Rhea-AI Filing Summary

Positive

Negative

Filing Explained

8-K Event Classification

Key Figures

Key Terms

Earnings Snapshot

FAQ

How much is MXCT paying for Akron Bio?

What were MXCT’s third-quarter 2026 revenue and net loss?

What restrictions apply to the MXCT acquisition shares?

Filing Exhibits & Attachments

Press Releases

Other Documents

Keep reading

More on MXCT

Trending in the feed